Exyte concludes integration of Pharmaplan: A-Z project execution of GMP facilities

Exyte announced the acquisition of Pharmaplan in September 2024 to establish a European market leader and deepen partnerships with the rapidly growing biotechnology and pharmaceutical sectors in Europe. Pharmaplan brings a network of locations and specialists across Europe, now operating within Exyte's Biopharma & Life Sciences organization.

"The full integration of Pharmaplan into the Exyte Group combines our global implementation expertise with five decades of experience in the fields of Life Sciences and Good Manufacturing Practices (GMP)," says Dr. Wolfgang Büchele, CEO of Exyte. "Our customers benefit from seamless EPC solutions – from concept design to regulatory-compliant handover. Facilities where pharmaceutical innovations become reality are delivered quickly, precisely, and reliably."

Since the announcement of the transaction, teams from both companies have collaborated to align systems and standards and to combine best practices from all disciplines. Through close cooperation, ongoing projects could be continued without interruption, and customer relationships maintained. Exyte has taken over and further expanded the customer relationships previously managed by Pharmaplan.

The response from the market and customers has been extremely positive. This is reflected in key project wins, robust new business, and very strong order development in 2025. Teams from both companies have also jointly secured projects outside Europe, including in Southeast Asia, highlighting the strength of the integrated structure. Exyte's global Biopharma and Life Sciences business unit is expected to achieve a record order intake in the current fiscal year.

Exyte assumes full responsibility for EPC/EPCM

Following the successful integration of Pharmaplan, Exyte now offers its Life Sciences services at more than 40 locations across twelve countries in Europe. This ensures the company’s presence near its customers in all major pharmaceutical and biotech markets in Europe. Exyte takes full responsibility for EPC/EPCM – from feasibility studies through concept and basic planning to detailed engineering, construction management, commissioning, CQV (Commissioning, Qualification, and Validation), and regulatory-compliant handover.

Exyte is one of the few global companies with the personnel resources and expertise to execute Life Sciences projects comprehensively from A to Z. The integration of Pharmaplan supports a growing European Life Sciences market characterized by trends such as mRNA platforms, cell and gene therapies, more resilient supply chains, and increasing sustainability requirements. In this environment, rapid deployment of qualified production capacities is a competitive advantage. Thanks to standardized methods and digital engineering, Exyte shortens time-to-market and ensures compliance with all legal requirements.

Global network of experts

Through a global network of specialists – many of whom are recognized as leaders in their fields – Exyte brings specialized know-how in process (CQV), HVAC (heating, ventilation, air conditioning), cleanroom technology, and regulatory requirements to successfully execute complex and highly regulated projects.

Digital engineering plays a central role: model-based design, 3D/4D planning, digital quality assurance and control (QA/QC), standardized commissioning, and data- and AI-supported methods embedded in proven workflows accelerate decision-making and ensure consistency on a large scale.

With over 50 years of experience in GMP-regulated facilities, Exyte is a pioneer in cleanroom and controlled manufacturing environments. The company develops methods that enable safe and rapid project execution. This track record is the reason why leading biopharmaceutical companies have trusted Exyte for decades.